Bausch & Lomb Q2 2026: Revenue Beat but EPS Misses by 6.5%
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Bausch & Lomb swung to GAAP operating profit and raised full-year guidance, powered by a 175% surge in premium intraocular lens revenue and 27% growth in its flagship pharmaceuticals MIEBO and XIIDRA. Cash flow from operations more than tripled to $153 million, though adjusted EPS of $0.15 missed consensus by 6.5%.
Continue ReadingShow less
Bausch & Lomb reported Q2 2026 revenue of $1.394 billion, topping the $1.368 billion consensus estimate by roughly 1.9%. The quarter marked a meaningful operational turning point, with the company swinging to a GAAP operating profit and raising its full-year guidance. Cash flow from operations more than tripled to $153 million, signaling improving financial health beneath the headline numbers.
The growth engine behind the quarter was a 175% surge in premium intraocular lens revenue, alongside 27% growth in its flagship pharmaceutical products MIEBO and XIIDRA. Those are eye-care-focused drugs that have become increasingly central to Bausch & Lomb's revenue mix, and their continued momentum gives the raised guidance some credibility.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
The one soft spot was adjusted EPS of $0.15, which came in about 6.5% below the consensus estimate of $0.16. Looking back at recent quarters, misses and beats have alternated with some regularity — the company beat in Q3 2025 and Q1 2026 but fell short in Q4 2025 and now Q2 2026. Investors will be watching whether the strong cash flow and guidance raise are enough to offset the earnings shortfall.
Mentioned: BLCO